Chat with us, powered by LiveChat Thailand Medical News - PR Releases
PR Releases
Presented by
Source: Eli Lilly and Company  Jan 20, 2019
REACH-2 is the first positive Phase 3 hepatocellular carcinoma trial in a biomarker-selected population known for poor prognosis   Pooled data analyses of AFP-High patients in the REACH-2 and REACH trials showed an improvement of 3.1 months in median overall survival   Eli Lilly and Company (NYSE: LLY) announced that results from the global Phase 3 REACH-2 study of CYRAMZA® (ram...
Source: Natera  Jan 07, 2019
                                                                                                                  ...
AstraZeneca  Jan 01, 2019
AstraZeneca announced a new collaboration with Cancer Research UK to launch a centre of excellence in genetic screening, cancer modelling and big data processing aimed at accelerating the discovery of new cancer medicines. The Functional Genomics Centre will further develop CRISPR technology to better understand the biology of cancer, creating biological models that may be more reflective of ...
Source: Roche  Nov 05, 2018
 • The phase III CLL14 study compared Venclexta/Venclyxto in combination with Gazyva/Gazyvaro to standard-of-care Gazyva/Gazyvaro plus chlorambucil  • Data will be submitted to health authorities and presented at an upcoming medical meeting     Basel,1 November 2018 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the randomised phase III CLL14 study, which ...
Source: AstraZeneca  Oct 30, 2018
Data show Lokelma maintained normokalaemia during days 8-29 of the maintenance phase in patients from four Asian countries   AstraZeneca today presented the results from the HARMONIZE Global Phase III trial, which investigated the safety and efficacy of Lokelma (sodium zirconium cyclosilicate) vs. placebo in patients with hyperkalaemia in Japan, Korea, Taiwan and Russia. The resul...